Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Milestone Pharmaceuticals Inc. MIST

Healthcare  —  Biotechnology
0.79 (0.01) (1.25%) as of 25 Sep
Market cap
$99.0M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Milestone Pharmaceuticals Inc. (MIST) Business Profile

Updated before January 2025

Company Overview

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative cardiovascular therapies. Founded in 2003 and headquartered in Montreal, Canada, the company has a strong focus on addressing unmet medical needs in the cardiovascular space. Milestone Pharmaceuticals is led by a team of seasoned professionals with extensive experience in drug development and commercialization. Key leadership includes Joseph Oliveto, who serves as the President and Chief Executive Officer, and Philippe Douville, the company’s founder and Chief Scientific Officer. The company also benefits from a robust board of directors and scientific advisory board, which provide strategic guidance and expertise.

Core Business Segments

Milestone Pharmaceuticals focuses primarily on the development of therapies for cardiovascular conditions. Its flagship product is etripamil, a novel, fast-acting calcium channel blocker designed for the acute treatment of paroxysmal supraventricular tachycardia (PSVT) and other episodic cardiovascular conditions. The company is also exploring the potential of etripamil in other indications, such as atrial fibrillation with rapid ventricular rate (AFib-RVR) and angina.

Key Products and Services

  • Etripamil for PSVT: Etripamil is Milestone’s lead investigational product. It is a nasal spray formulation that provides patients with a convenient, self-administered option for managing PSVT episodes. The product is currently in late-stage clinical trials and has shown promising results in reducing the need for emergency medical intervention.
  • Pipeline Development: Beyond PSVT, Milestone is actively investigating the use of etripamil for other cardiovascular conditions. The company’s pipeline reflects its commitment to expanding its portfolio and addressing broader unmet needs in the cardiovascular space.

Business Model

Milestone Pharmaceuticals operates as a research-driven organization with a focus on developing innovative therapies that address significant unmet medical needs. The company’s business model revolves around the following key components:

  1. Research and Development (R&D): Milestone invests heavily in R&D to advance its pipeline of cardiovascular therapies. The company collaborates with leading academic institutions and clinical research organizations to ensure the highest standards of scientific rigor.
  2. Regulatory Approvals: A significant portion of Milestone’s efforts is dedicated to navigating the regulatory landscape to bring its products to market. The company works closely with regulatory agencies such as the FDA to ensure compliance and expedite approvals.
  3. Commercialization Strategy: Milestone plans to commercialize its products through a combination of direct sales and strategic partnerships. The company aims to build a robust sales and marketing infrastructure to support the launch of etripamil and other future products.
  4. Revenue Generation: Milestone’s revenue model is based on the successful commercialization of its therapies. The company anticipates generating revenue through product sales, licensing agreements, and potential milestone payments from partners.

Strategic Direction

Milestone Pharmaceuticals is committed to becoming a leader in the cardiovascular therapeutics space. The company’s strategic priorities include:

  • Advancing Etripamil: Milestone’s immediate focus is on completing the clinical development of etripamil for PSVT and securing regulatory approval. The company is also exploring additional indications for the drug to maximize its therapeutic potential.
  • Expanding the Pipeline: Milestone aims to leverage its expertise in calcium channel blockers to develop new therapies for other cardiovascular conditions. The company is actively evaluating opportunities to expand its pipeline through internal R&D and strategic acquisitions.
  • Global Market Expansion: Milestone plans to expand its presence in key international markets, including Europe and Asia, to reach a broader patient population.
  • Sustainability Goals: While not a primary focus, Milestone is committed to operating in an environmentally and socially responsible manner. The company aims to minimize its environmental footprint and contribute positively to the communities it serves.

Competitive Landscape

Milestone Pharmaceuticals operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Pharmaceutical Giants: Companies like Pfizer, Novartis, and Bristol-Myers Squibb have established cardiovascular portfolios and significant resources for R&D and commercialization.
  • Specialty Biopharma Companies: Smaller companies such as Correvio Pharma and Cytokinetics also focus on cardiovascular therapies and represent direct competition in specific niches.
  • Generic Drug Manufacturers: The availability of generic alternatives for certain cardiovascular conditions poses a competitive challenge for Milestone’s branded therapies.

Despite the competition, Milestone differentiates itself through its focus on episodic cardiovascular conditions and its innovative nasal spray formulation of etripamil.

Risk Factors

Milestone Pharmaceuticals faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The approval process for new drugs is complex and uncertain. Delays or rejections by regulatory agencies could significantly impact the company’s timeline and revenue projections.
  • Market Dependence: Milestone’s success is heavily reliant on the commercialization of etripamil. Failure to achieve market acceptance could adversely affect the company’s financial performance.
  • Supply Chain Disruptions: As a clinical-stage company, Milestone depends on third-party manufacturers and suppliers. Any disruptions in the supply chain could delay product development and commercialization.
  • Competition: The biopharmaceutical industry is highly competitive, and Milestone faces the risk of being outpaced by competitors with greater resources.
  • Financial Risks: As a clinical-stage company, Milestone has limited revenue streams and relies on external funding to finance its operations. The company may face challenges in securing additional capital.

Recent Developments

Milestone Pharmaceuticals has made significant progress in recent years:

  • Clinical Trials: The company has successfully completed several late-stage clinical trials for etripamil, demonstrating its efficacy and safety for the treatment of PSVT.
  • Regulatory Milestones: Milestone has engaged in productive discussions with the FDA and other regulatory agencies to advance the approval process for etripamil.
  • Partnerships: The company has entered into strategic collaborations with leading pharmaceutical companies to support the development and commercialization of its therapies.
  • COVID-19 Impact: Like many biopharmaceutical companies, Milestone faced challenges during the COVID-19 pandemic, including delays in clinical trials. However, the company has since resumed normal operations and remains on track to achieve its strategic goals.

Investment Considerations

Strengths

  • Innovative Product: Etripamil’s unique nasal spray formulation offers a significant advantage over existing therapies for PSVT.
  • Focused Strategy: Milestone’s specialization in episodic cardiovascular conditions allows it to address a niche market with high unmet needs.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Strong Pipeline: Milestone’s pipeline reflects its commitment to innovation and long-term growth.

Risks

  • Regulatory Uncertainty: The approval process for new drugs is inherently risky and could impact the company’s timeline.
  • Market Dependence: Milestone’s reliance on a single product increases its exposure to market risks.
  • Financial Constraints: As a clinical-stage company, Milestone may face challenges in securing additional funding.

Conclusion

Milestone Pharmaceuticals Inc. is well-positioned to become a leader in the cardiovascular therapeutics space. With its innovative approach to drug development, strong leadership, and commitment to addressing unmet medical needs, the company has significant growth potential. However, investors should carefully consider the risks associated with regulatory approvals, market dependence, and financial constraints. Overall, Milestone represents a compelling investment opportunity for those seeking exposure to the biopharmaceutical sector.